BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 BEST SELLING CANCER DRUGS 2025 Rank Brand Company Indications Revenues $ billion 1 Keytruda Merck Melanoma, NSCLC, HNSCC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $31.7 2 Darzalex Johnson and Johnson Multiple myeloma $14.5 3 Opdivo Bristol Myers Squibb Melanoma, NSCLC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $10.0 4 Tagrisso AstraZeneca EGFR positive NSCLC $7.2

JOHNSON AND JOHNSON Nipocalimab Shows Stronger Phase 2 Signal in Autoantibody-High Sjögren’s Disease Nipocalimab is attracting attention at EULAR 2026 as a potential new option for patients with Sjögren’s disease who have a high autoantibody burden. Fresh Phase 2 data from the DAHLIAS study suggest that the patients with the most pronounced serologic activity may be the ones who gain the greatest clinical benefit. Signal in patients with high autoantibody and IgG levels DAHLI

ASTRAZENECA STRIDE Plus Lenvatinib and TACE Cuts Progression Risk by 30% in Embolisation‑Eligible Unresectable HCC Early EMERALD‑3 results indicate that combining dual checkpoint blockade and lenvatinib with TACE can prolong disease control in patients with embolisation‑eligible, unresectable hepatocellular carcinoma, without introducing new safety concerns. How EMERALD‑3 was designed? EMERALD‑3 is a Phase III study enrolling people with unresectable HCC who are suitable fo

Pfizer and Innovent Biologics have formed a broad global partnership aimed at advancing a new generation of oncology therapies, focusing on early-stage and newly discovered cancer treatment candidates. Also read: Top 10 Pharma Companies by Revenue in 2025 The agreement covers the joint development of 12 innovative drug programs, including antibody-drug conjugates (ADCs) featuring novel payload technologies and multispecific antibodies engineered to enhance immune system engag

AstraZeneca’s Imfinzi (durvalumab) has received approval in the United States as part of the first and only immunotherapy-based combination regimen for adults with previously untreated, high-risk non-muscle-invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin (BCG). The approval allows the use of Imfinzi alongside both induction and maintenance BCG therapy in this patient population. The regulatory decision is supported by findings from the Phase III

CVS Caremark is repositioning its GLP-1 weight management strategy to focus on both affordability and broader access, instead of simply expanding coverage as a routine update. The key operational moves are the reintroduction of Zepbound (tirzepatide) as a preferred option on its commercial formularies from October 1, 2026, and the removal of the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy, effective June 1, 2026. These decisions indicate that CVS Car

Decnupaz (pivekimab sunirine) has received U.S. FDA approval for use in adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare and aggressive blood cancer with few effective therapies available. This medicine is an antibody-drug conjugate (ADC) and is notable because treatment can be started in the outpatient setting rather than requiring admission to the hospital. It also represents AbbVie’s first ADC approved in the hematology/oncology space.

The Saudi Food and Drug Authority (SFDA) has granted Novo Nordisk’s therapy, denecimig, designation as a “promising drug.” The therapy is intended for long-term use to prevent or reduce bleeding episodes in patients with hemophilia A across different age groups, regardless of the presence of factor VIII inhibitors. Denecimig, a bispecific antibody belonging to a class of protein-based therapies. It works by binding to two key proteins involved in the blood clotting process,

A study mission focused on the European Health Technology Assessment (HTA) framework, involving the Spanish Agency for Medicines and Health Products (AEMPS), has officially wrapped up following a visit to Italy. The initiative, titled “Supporting AEMPS in the implementation of the HTA Regulation, study visit to Italy,” was conducted under the European Commission’s TAIEX Technical Support Instrument (TSI). This engagement provided a valuable platform for both technical excha

The Italian Medicines Agency (AIFA) has issued an updated overview of medicinal products and anti-infective therapies recognized for their level of therapeutic advancement as of April 30, 2026. These updates are based on assessments conducted by the Scientific and Economic Commission, which determines whether a medicine qualifies as therapeutically innovative. Also read: Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? Medicines Granted Innovative Status in Italy i

Eli Lilly has entered into three separate acquisition agreements aimed at strengthening its position in the infectious disease space, targeting both viral and bacterial threats associated with long-term health complications. The deals involve Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc., marking a significant step in Lilly’s broader strategy to invest in innovative prevention-focused technologies. These acquisitions reflect Lilly’s renewed emphasis on comba

VERVE-102 Shows Durable LDL Reduction in Heart-2 Study, Lilly Plans Phase 2 Launch Eli Lilly has released early clinical results for its gene-editing candidate VERVE-102, highlighting the potential of a single-dose treatment to deliver sustained reductions in LDL cholesterol among high-risk patients. The investigational therapy targets the PCSK9 gene in the liver, aiming to permanently reduce its activity and lower circulating cholesterol levels. In the ongoing Phase 1b Heart

On May 22, 2026, the German Bundestag approved the Pharmacy Services Development Act, known as ApoVWG, introducing wide-ranging reforms to reinforce the country’s pharmacy network and expand patient care services. The legislation is designed to secure consistent access to medicines across Germany, with a strong focus on underserved rural regions. It combines financial support, regulatory simplification, and expanded professional responsibilities for pharmacies. Financial

The US Food and Drug Administration has approved Datroway, developed by AstraZeneca and Daiichi Sankyo, as the first TROP2-directed antibody drug conjugate cleared for first-line treatment of metastatic triple-negative breast cancer in patients who are not suitable candidates for PD-1 or PD-L1 inhibitor therapy. This approval marks a significant shift in how this difficult-to-treat cancer may be managed going forward. What is Datroway and Why Does This Approval Matter? Datr

As the global geopolitical landscape shifts, Europe is reassessing its position in the pharmaceutical sector, aiming to protect its strategic autonomy while maintaining global competitiveness. A joint declaration by Germany and France highlights a renewed commitment to strengthening Europe’s pharmaceutical industry amid rising international pressures and structural challenges. What Makes Europe a Key Pharmaceutical Market? With a population of nearly 520 million across the

Eli Lilly has reported strong top-line outcomes from its Phase 3 TRIUMPH-1 study, highlighting the significant weight reduction potential of its investigational obesity therapy, retatrutide. The once-weekly triple receptor agonist targets GIP, GLP-1, and glucagon pathways, positioning it as a next-generation metabolic treatment. Also read: Top 10 Pharma Companies by Revenue in 2025 The late-stage trial evaluated adults living with obesity or overweight conditions accompanied

Top 10 healthcare companies by revenues | 2026 Rank Company Q1 H1 9M 2026 revenues 1 United Health Group $111.7 2 CVS Health $100.4 3 Cigna Group $68.5 4 Centene $49.9 5 Elevance Health $49.5 6 Humana $39.6 7 Kaiser Permanente $34.6 8 HCA Healthcare $19.1 9 HCSC $16.6 10 Molina Healthcare $10.8 Top Healthcare Companies by Revenues | 2026 United Health Group Q1 REVENUES: UnitedHealth Group reported first-quarter 2026 revenues of $111.7 billion, representing a 2% increase from

Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies

The Council of Economic Advisers has published a detailed analysis of the Trump Administration’s Most-Favored-Nation (MFN) drug pricing framework, outlining how the policy could deliver substantial savings to U.S. patients and public programs while rebalancing who pays for pharmaceutical innovation worldwide. The framework combines voluntary agreements with major manufacturers, new reference pricing rules, and targeted reforms to Medicaid, direct‑to‑consumer markets, and Medi

Baxfendy FDA Approval for Hypertension AstraZeneca has received US FDA approval for Baxfendy (baxdrostat), the first and only aldosterone synthase inhibitor (ASI) indicated for the treatment of hypertension in adults whose blood pressure remains uncontrolled despite standard therapies. Baxfendy is approved for use in combination with other antihypertensive medications, offering a new treatment option for patients with resistant or difficult-to-control hypertension. Also re

Novartis’ Pluvicto Shows Deeper PSA Responses in Hormone-Sensitive Prostate Cancer Novartis has reported new findings from the PSMAddition trial showing that Pluvicto (lutetium-177 vipivotide tetraxetan), when added to standard therapy, significantly improves prostate-specific antigen (PSA) outcomes in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The data indicate that combining Pluvicto with standard of care, comprising an androgen recept

BeOne Medicines announced that the U.S. FDA has granted accelerated approval to Beqalzi (sonrotoclax), the first and only BCL2 inhibitor approved for relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States. Also read: Top 10 U.S. healthcare companies by 2026 revenue Beqalzi is approved for adult patients who have received at least two prior systemic therapies, including a Bruton’s tyrosine kinase (BTK) inhibitor. This marks the first new BCL2 inhibitor ap

AstraZeneca has introduced K+ Connect, a nationwide initiative aimed at improving the management of hyperkalemia among patients with heart failure (HF) and chronic kidney disease (CKD) in India. The program brings together 33 leading tertiary care institutions to promote coordinated, multidisciplinary care and establish a network of Centers of Excellence dedicated to tackling hyperkalemia. Also read: NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive

NICE backs routine NHS access to Spinraza and Evrysdi for SMA People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two disease‑modifying therapies after NICE issued final draft guidance recommending nusinersen and risdiplam for use on the NHS. The decision moves both medicines out of managed access arrangements into standard commissioning, providing long‑term certainty for patients and families. Also read: European Congress on Obesit

Novo Nordisk’s Oral Wegovy Shows 21.6% Weight Loss in Early Responders in OASIS 4 Trial Novo Nordisk has reported new clinical data showing that its investigational oral version of Wegovy (semaglutide 25 mg) achieved significant weight loss and functional improvements in adults with obesity. In the OASIS 4 trial, nearly 29% of participants were classified as early responders, defined as achieving at least 10% weight loss by week 16. This group recorded an average weight reduc

UnitedHealthcare is rolling back prior authorization requirements for a substantial share of its book of business, in a move the company says is aimed at cutting red tape and speeding access to care. The insurer plans to drop prior authorization for 30% of services that previously needed approval and has set a goal to remove an additional 30% of remaining authorizations by the end of 2026, covering categories such as select outpatient surgeries, echocardiograms, outpatient th

Sl No Brand Q1 H1 9M Total 1 Johnson and Johnson $24.0 2 Eli Lilly $19.8 3 Roche $18.8 4 AstraZeneca $15.3 5 Novo Nordisk $15.2 6 AbbVie $15.0 7 Pfizer $14.4 8 Merck $14.3 9 Novartis $13.1 10 Sanofi $12.4 Top pharmaceutical companies by revenues | 2026 JOHNSON AND JOHNSON Q1 REVENUES: In the first quarter of 2026, the company reported total sales of $24.1 billion, reflecting a 9.9% increase. Revenue from Innovative Medicines reached $15.4 billion. Global operational sales in

AbbVie Showcases New Real-World IBD Data for Skyrizi and Rinvoq at DDW 2026 AbbVie’s latest inflammatory bowel disease (IBD) data package from Digestive Disease Week (DDW) 2026 underscores the growing clinical role of Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn’s disease and ulcerative colitis. Real-world results from the ASPIRE-CD study showed that adults with moderately to severely active Crohn’s disease treated with risankizumab achieved rapid and sustained r

The U.S. FDA has approved Foundayo (orforglipron), a once‑daily GLP‑1 tablet for chronic weight management in adults with obesity or overweight and weight‑related comorbidities. It is currently the only GLP‑1 pill for weight loss that can be taken at any time of day without specific restrictions on food or water intake. Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval Backed by the phase 3 ATTAIN programme, Foundayo delivered clinically meaningful and sustai

The European Commission has granted conditional marketing authorisation for Sanofi’s Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and adolescents aged 12 years and older who weigh at least 40 kg. The approval offers a critical treatment option for patients who have limited benefit from current therapies or have exhausted existing options. Also read: Top 10 Pharmaceutical Companies by Revenue 2025 The decision is supported by evidence from

Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response. This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic

Johnson & Johnson Reports Encouraging Early Results for Erda‑iDRS in Intermediate‑Risk Non-Muscle Invasive Bladder Cancer Johnson & Johnson unveiled promising data from a Phase 1, open-label, multicenter clinical trial investigating its novel intravesical drug-release system containing erdafitinib (known as Erda‑iDRS, formerly TAR‑210) in patients with intermediate‑ and high‑risk non–muscle‑invasive bladder cancer (NMIBC) whose tumors carry specific FGFR (fibroblast growth fa

DEMOGRAPHICS The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments to provide health care services to citizens. The funding for healthcare in India is 3% of GDP and is continuously decreasing since (3.75% in 2013). Government spending currently accounts for 1% of GDP, and the Indian government aims to increase it to 2.5% by 2025. The infant mortality rate was reduced from 88/1,000 in 1990 to 32/1,000 in 2

The U.S. Food and Drug Administration (FDA) has granted approval for Sotyktu (deucravacitinib), an oral, selective inhibitor of tyrosine kinase 2 (TYK2), for use in adult patients with active psoriatic arthritis (PsA). This marks the first approval of a TYK2 inhibitor for this condition in the United States. The decision was supported by positive outcomes from two pivotal Phase 3 clinical studies, POETYK PsA-1 and POETYK PsA-2, which evaluated the efficacy and safety of deucr

Johnson & Johnson has received U.S. FDA approval for the combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy that included a proteasome inhibitor and an IMiD. The FDA reached this decision 55 days after submission, making it the third approval granted through the Commissioner’s National Priority Voucher (CNPV) pilot program. The regimen can no

Roche reported encouraging mid‑stage results for petrelintide, a once‑weekly amylin analogue being developed as a novel option for people with overweight and obesity. In the 42‑week ZUPREME‑1 trial, which enrolled 493 adults with a mean BMI of about 37 kg/m² on background diet and exercise, all five petrelintide dose regimens achieved statistically significant and clinically meaningful weight loss versus placebo at week 28, meeting the primary endpoint. Weight reduction conti

Roche’s BTK inhibitor fenebrutinib delivers strong efficacy in relapsing multiple sclerosis, opening up a potential multi‑billion‑dollar revenue opportunity for the company Roche’s BTK inhibitor fenebrutinib has generated a third consecutive Phase III success in multiple sclerosis, strengthening its positioning as a potential first-in-class option across both relapsing and progressive forms of the disease. What clinical benefits fenebrutinib show in clinical trials? In the la

The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the first licensed treatment for vitiligo to be used in the NHS, providing a new option for more than 80,000 people in England living with the condition. Vitiligo is a chronic autoimmune disorder in which the immune system attacks melanocytes, the cells responsible for skin pigmentation. This leads to pale or white patches on the skin, which can have a considerable effect on

Keytruda and Welireg Combination Cuts Risk of RCC Recurrence by 28% in Adjuvant Setting Merck reported new Phase 3 results from the LITESPARK-022 trial showing that adding Welireg (belzutifan) to Keytruda (pembrolizumab) as adjuvant therapy significantly reduced the likelihood of recurrence or death in certain patients with clear cell renal cell carcinoma (RCC) following nephrectomy. The study demonstrated a 28% lower risk of disease recurrence or death compared with Keytruda

Novo Nordisk Semaglutide Price Cut 2027: Wegovy & Ozempic List Price Drops to $675 Amid Eli Lilly Zepbound Competition Novo Nordisk announced that it will cut the U.S. list price of its leading semaglutide‑based medicines, Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, marking a significant step to improve affordability and access to GLP‑1 therapies for obesity and type 2 diabetes The price reduction, representing up to 50% off for Wegovy and 35% for

CagriSema produced large absolute weight loss in REDEFINE 4 but failed its main goal of matching Eli Lilly’s tirzepatide, raising questions about its competitive positioning in obesity. CagriSema delivers strong weight loss, but not enough vs tirzepatideIn the open‑label phase 3 REDEFINE 4 trial, adults with obesity and at least one comorbidity were randomized to once‑weekly CagriSema (fixed‑dose cagrilintide 2.4 mg plus semaglutide 2.4 mg) or tirzepatide 15 mg, both given su

Does Novartis remibrutinib work for chronic inducible urticaria? Yes, first Phase III success in 3 CIndU types Oral remibrutinib hit primary endpoint vs. placebo at week 12 in RemIND trial, with complete responses in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Rhapsido CIndU approval status Novartis seeks FDA approval for dermographism (most common form of CIndU). Why This Matters First targeted therapy for CIndU, affecting ~29M adults worldwide Sa

Eli Lilly shared encouraging early findings from the innovative TOGETHER-PsO trial, testing ixekizumab (Taltz) alongside tirzepatide (Zepbound) against ixekizumab solo in patients facing moderate-to-severe plaque psoriasis plus obesity or excess weight and related health issues. Trial Achieves Dual Goals After 36 weeks, those getting both drugs saw far better outcomes on the main goal, full skin clearing (PASI 100 score) paired with 10%+ body weight drop, outpacing the ixekiz

Amgen has secured European Commission clearance for Uplizna (inebilizumab) as an add‑on therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti‑acetylcholine receptor (AChR) or anti‑muscle‑specific tyrosine kinase (MuSK) antibodies. The decision introduces a targeted B‑cell–depleting option that can be given as two loading infusions followed by maintenance dosing twice a year, with the aim of providing sustained disease control alongside existin

Exdensur (depemokimab), GSK’s new ultra‑long‑acting anti‑IL‑5 biologic, has been granted marketing authorisation by the European Commission for two respiratory indications: severe asthma driven by type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). It is the first biologic in the EU that can be used across respiratory diseases with a twice‑yearly dosing schedule, and the approval is supported by four phase III studies – SWIFT‑1, SWIFT‑2, ANCHOR‑1 and AN

Get the definitive ranking of the top-selling pharmaceutical drugs by global revenue in 2025. See which blockbusters—from Keytruda to the GLP-1 therapies like Ozempic and Mounjaro—are leading the market and driving record sales in Oncology and Immunology.

Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, a biotechnology firm pioneering the development of immune cell therapies engineered directly within the body. The transaction is valued at up to $2.4 billion, including an upfront payment and milestone-based potential payouts. Also read: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa Advancing In Vivo CAR-T and Genetic Medicine Orna Therapeutics is building a pi

UCB has released long-term BE HEARD trial data showing that bimekizumab (Bimzelx) delivered deep and durable improvements in hidradenitis suppurativa over three years, with results showcased at the European Hidradenitis Suppurativa Foundation (EHSF) 2026 meeting. The new analyses highlight bimekizumab’s capacity not only to clear inflammatory lesions but also to remodel disease severity categories and reduce structurally destructive draining tunnels over time. Long-term HS re

Roche has released new late-breaking Phase III data demonstrating that its experimental Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib showing potential in patients with primary progressive multiple sclerosis (PPMS). Findings from the pivotal FENtrepid trial, presented at the ACTRIMS forum, indicate that fenebrutinib met its primary endpoint of non-inferiority to the current standard therapy, OCREVUS (ocrelizumab), in delaying disability progression among people with

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for AstraZeneca’s Biologics License Application (BLA) seeking approval of Saphnelo (anifrolumab) for subcutaneous administration in adults with systemic lupus erythematosus (SLE). This is despite Saphnelo SC meeting primary endpoint in clinical trial. AstraZeneca has provided the additional information requested and stated its commitment to working closely with the FDA to advance the appli